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SETTLEMENT OF INDIA/EU WTO DISPUTE RE
SEIZURES OF IN-TRANSIT MEDICINES:
WHY THE PROPOSED EU BORDER
REGULATION ISN‟T GOOD ENOUGH
Professor Brook K. Baker1
ABSTRACT
European Customs officials have used fictive patent rights to justify the
seizure of lawful generic medicines produced in India and destined for nonEuropean markets. Following a public outcry and initiation of two WTO
complaints, the EU has proposed amendments to Border Regulations
Measure 1383/2003. The Proposed Border Regulation in its current form
will not adequately resolve the risk of interception in Europe of medicines
lawfully manufactured and exported from India and destined for lawful
import and consumption in a non-EU country. This analysis concludes that
multiple weaknesses remain in the Border Regulations, including: (1)
continued coverage of alleged patent and supplemental protection certificate
infringement claims that can be based on fictional patent status under
national law; the addition of utility models; and continued coverage of
design rights and civil trademark infringement matters that are more
appropriately addressed in ordinary court proceedings; (2) inappropriate
application of the law of the in-transit country instead of the law of the
importing country when assessing an IP infringement claim; (3) unclear
directives to “consider” the risk of diversion to EU markets with no explicit
prohibition against seizing in-transit medicines in the absence of such a
showing and without requirement of clear and convincing evidence of an
imminent diversion by an identified party; (4) insufficient opportunities to
be heard for declarants and holders of goods; and (5) insufficient remedies
for declarants and holders of goods and for purchasers and consumers who
are proximately harmed by unsuccessful border applications.
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I.

INTRODUCTION

On July 28, 2011, the Ministry of Commerce and Industry of the
Government of India announced an “Understanding” in principle with the
European Union (EU) concerning a pending World Trade Organization
(WTO) complaint challenging EU customs measures that had been used to
justify seizures of Indian generic medicines in transit through Europe to
destinations in Latin America, Oceania, and Africa.2 These seizures and the
EU‟s delayed and defensive response3 to early and repeated expressions of
diplomatic and human rights concerns4 prompted India and Brazil to initiate
dispute resolution procedures – namely preliminary requests for
2

Press Release, Government of India Ministry of Commerce and Industry, Indian EU
Reach an Understanding on Issue of Seizure of Indian Generic Drugs in Transit (July 28,
2011), available at http://pib.nic.in/newsite/erelease.aspx?relid=73554.
3
See WTO General Council, Minutes of Meeting, WT/ GC/M/118 (Feb. 3, 2009),
available at
http://docsonline.wto.org/GEN_highLightParent.asp?qu=&doc=D%3A%2FDDFDOCUM
ENTS%2FT%2FWT%2FGC%2FM118.DOC.HTM . (arguing that BMR was fully TRIPScompliant and that Europe was acting benevolently to prevent trade in “counterfeit”
medicines that were a risk to public health in developing countries).
4
See, e.g., Intervention by India, Agenda Item ‘M’ – Other Business – Public Health
dimension of the TRIPS Agreement (Feb. 4, 2009), available at http://www.ipwatch.org/weblog/wp-content/uploads/2009/03/intervention-by-india.doc; Statement by
Brazil, TRIPS Council Agenda Item M (Other Business), Public Health Dimension of the
TRIPS Agreement, (Feb. 4, 2009), available at
http://keionline.org/blogs/2009/03/04/brazilian-intervention-at-trips-council; Letter from
various NGOs to the Director Generals of the WHO and the WTO Feb. 18, 2009, available
at http://keionline.org/misc-docs/seizures/WHO_seizures_18feb.pdf; UNITAID Statement
on Dutch Confiscation of Medicines Shipment, available at
http://www.unitaid.eu/en/resources/news/156-unitaid-statement-on-dutch-confiscation-ofmedicines-shipment.html; World Health Organization [WHO], Statement – Access to
Medicines (March 13, 2009), available at
http://www.who.int/mediacentre/news/statements/2009/access-medicines20090313/en/index.html.
WWW.WCL.AMERICAN.EDU/PIJIP
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consultations – against the EU at the World Trade Organization.5
Pursuant to the announced Understanding, the European Union will no
longer intercept in-transit generic medicines unless there is adequate
evidence to satisfy customs authorities that there is a substantial likelihood
of diversion of such medicines to the EU market. In addition, the EU is to
issue interim guidelines advising member countries how border
enforcement should be done. Finally, the EU has proposed a new
Regulation (Proposed Border Regulation)6 to replace challenged Council
Regulation (EC) No. 1383/2003, the so-called Border Measures Regulation
(BMR 1383/2003).7 Although India does not completely endorse the
phrasing of the draft proposal, India will convey its views on the proposal to
EU during the expected 12-18 month approval process.8 There are reports
that India does not consider the draft strong enough to satisfy its
requirements.9
In exchange for these undertakings and as long as they are adhered to,
5

Request for Consultations by India, European Union – Seizure of Generic Drugs in
Transit, WT/DS408 (May 11, 2011), available at
http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds408_e.htm; Request for
Consultations by Brazil, European Union – Seizure of Generic Drugs in Transit,
WT/DS409, available at
http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds409_e.htm. The consultations
were protracted and included premature claims of settlement. See generally Consultations
on WTO Drug Transit Case Continue, Intellectual Property Watch, Sept. 16, 2010,
available at http://www.ip-watch.org/weblog/2010/09/16/consultations-on-wto-case-ondrugs-in-transit-continue/; C.H. Unnikrishan, India may move WTO as it seeks to resolve
EU dispute, livemint.com&WSJ (Oct. 10, 2010),
http://www.livemint.com/2010/10/11225420/India-may-move-WTO-as-it-seeks.html;
Kaitlin Marla, Minister, India Anticipates European Fix to Law Delaying Generic
Shipments, IP-WATCH (Oct. 20, 2010), available at http://www.ipwatch.org/weblog/2010/10/20/ambassador-india-anticipates-european-fix-to-law-delayinggenerics-shipments/.
6
Proposal for a Regulation of the European Parliament and of the Council
Concerning Customs Enforcement of Intellectual Property Rights, COM(2011) 285 final
(May 25, 2011), [hereinafter Proposed Border Regulation], available at
http://ec.europa.eu/taxation_customs/resources/documents/customs/customs_controls/
counterfeit_piracy/legislation/com285_en.pdf.
7
Council Regulation 1383/2003, 2003 O.J. (L 196/7), available at http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:196:0007:0014:EN:PDF.
8
Asit Ranjan Mishra, Generic drugs seizure row: India, EU Reach ‘Interim
Settlement,’ livemint.com&WSJ (July 29, 2011),
http://www.livemint.com/articles/2011/07/28221918/Generic-drugs-seizure-rowInd.html?atype=tp.
9
Matthias Williams, Update 2-India, EU Health Drugs Seizures Dispute with Interim
Agreement, REUTERS (July 28, 2011), http://www.reuters.com/article/2011/07/28/india-eudrugs-idUSL3E7IS4WW20110728.
WWW.WCL.AMERICAN.EDU/PIJIP
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India has assured the EU that it will not request the establishment of a
dispute settlement panel at the WTO. However, India retains the option to
revive the dispute if the EU does not abide by the core principles agreed to
in the Understanding.10 This Understanding between the EU and India does
not directly impact the parallel WTO dispute filed by Brazil, but as a
practical matter, Brazil‟s dispute is likely to be suspended pending final
enactment of the new Regulation.
The question arises whether India is correct that the Proposed Border
Regulation in its current form will not adequately resolve the risk of
interception in Europe of medicines lawfully manufactured and exported
from India and destined for lawful import and consumption in a non-EU
country. This analysis concludes that multiple weaknesses remain,
including:
1. continued coverage of alleged patent and supplemental protection
certificate infringement claims that can be based on fictional patent
status under national law; the addition of utility models; and
continued coverage of design rights and civil trademark
infringement matters that are more appropriately addressed in
ordinary court proceedings;
2. inappropriate application of the law of the in-transit country instead
of the law of the importing country when assessing an IP
infringement claim;
3. directives to “consider” the risk of diversion to EU markets with no
explicit prohibition against seizing in-transit medicines in the
absence of such a showing and without requirement of clear and
convincing evidence of an imminent diversion by an identified
party;
4. insufficient opportunities to be heard for declarants and holders of
goods; and
5. insufficient remedies for declarants and holders of goods and for
purchasers and consumers who are proximately harmed by
unsuccessful border applications.
Unless these public health weaknesses are addressed, India‟s WTO
complaint should not be withdrawn. Moreover, the Proposed Border

10

EU Agrees to Stop Confiscation of India Generic Drugs, THE ECONOMIC TIMES
(July 29, 2011), http://articles.economictimes.indiatimes.com/2011-0729/news/29829346_1_customs-regulations-indian-generic-drugs-international-intellectualproperty-agreement.
WWW.WCL.AMERICAN.EDU/PIJIP
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Regulation should be rejected by the European Council in its present form.
II.

BRIEF BACKGROUND TO THE PROPOSED REGULATION

Between 2008 and 2009 Dutch, and on one occasion German, customs
officials detained nearly 20 shipments of generic medicines11 under the
authority of BMR 1383/2003. When interpreting BMR 1383/2003, Dutch
customs authorities applied the judicially created rule that the IP status of
in-transit medicines should be judged under the fiction that the medicines
had been manufactured in the Netherlands.12 This interpretation was based
at least in part on recital no. 8 of BMR 1383/2003 which reads
“Proceedings initiated to determine whether an intellectual property right
has been infringed under national law will be conducted with reference to
the criteria used to establish whether goods produced in that Member State
infringe intellectual property rights.” (Emphasis added.) In some
circumstances, customs officials acted ex officio to initiate temporary
seizures based on suspicion of domestic patent law violation under the
manufacturing fiction. However, they continued such seizures based on
applications by Big Pharma, which requested impounding and delaying
shipments of life-saving medicines bound from India, where they had been
lawfully manufactured and exported, to countries in Africa, Oceania, and
Latin America, where they would have been lawfully imported, marketed
and consumed. 13 Most of the medicines were seized on the basis of
11

John Miller & Geeta Anand, India Prepares EU Trade Complaint, WALL ST. J.
(August 6, 2009), available at
http://online.wsj.com/article/SB124949598103308449.html?mod=3Dgooglenews_wsj.
12
Rechtbanks-Gravenhage [District Court in The Hague], 18 juli 2008, IER 2008, 83
m.nt. J.G. Kuhlmann (Sosecal v. Sisvel) (Neth.), ), available at
http://www.eplawpatentblog.com/PDF_December09/The%20Hague%20DC%20Sisvel%20
v%20Sosecal%20EN.pdf ; see Frederick J. Abbott, Seizures of Generic Pharmaceuticals in
Transit Based on Allegations of Patent Infringement: A Threat to International Trade,
Development and Public Welfare, 1 W.I.P.O.J. 43, 47 (2009), available at
http://www.wipo.int/about-wipo/en/wipo_journal/pdf/wipo_journal_1_1.pdf; Frank
Eijsvogels, SISVEL V. SOSECAL: ACTING AGAINST TRANSIT GOODS STILL POSSIBLE UNDER
THE ANTI P IRACY REGULATION IN THE NETHERLANDS, IP Intelligence Eur. 10 (Howrey
L.L.P., Amsterdam, Netherlands), 2008.
13
E.g., Letter from Merck and Du Pont lawyers to Dr. Reddy‟s Laboratory, Inc.
(December 24, 2008 ), available at
http://online.wsj.com/public/resources/documents/eudrugs2009letter1.pdf (stating “the
Court in the Netherlands has determined that products in transit qualify as products
infringing intellectual property rights where this would have been the case if the goods
would have been manufactured in the Netherlands); Letter sent by Eli Lilly lawyers to
Cipla (December 09, 2008), available at
WWW.WCL.AMERICAN.EDU/PIJIP
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fictional patent violations, but in at least one other instance, generic
medicines were seized by over-zealous German customs officials on the
premise that the generic medicine, “amoxicillin,” which as required bore the
international non-proprietary name, had a “brand” confusingly similar to
GlaxoSmithKline‟s trademark protected medicine “Amoxil.”14 After these
multiple seizures, customs authorities required that the suspect medicines be
destroyed, returned to India, or on occasion onward shipped on a delayed
basis to their ultimate destination.15
Leading European scholars opined that it was unlawful under European
Council law to apply BMR 1383/2003 to truly in-transit medicines –
medicines not destined for or likely to be diverted to European Markets.16
The application of fictional IP patent and trademark rights to medicines-intransit was also roundly criticized by these same scholars 17 and by India18
for violating core principles of the Agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS or TRIPS Agreement),19 including
Articles 2, 28, 31, 41, 42, and 52, Articles V and X of the General
http://online.wsj.com/public/resources/documents/eudrugs2009letter3.pdf (concerning
Olanzapine en route from India to Peru).
14
European Generic Drug Seizures Take Centre Stage at TRIPS Council Meeting, 13
BRIDGES WEEKLY TRADE NEWS DIGEST (June 10, 2009), available at
http://ictsd.org/i/news/bridgesweekly/48330/.
15
Press Release, supra note 2.
16
See, e.g., Henning Grosse Ruse-Khan & Thomas Jaeger, Policing Patents
Worldwide? EC Border Measures against Transiting Generic Drugs under EC- and WTO
Intellectual Property Regimes, 40 INT'L REV. INTELL. PROP. & COMPETITION L. 502 (2009);
contra Xavier Seuba, Free Trade of Pharmaceutical Products: The Limits of Intellectual
Property Enforcement at the Border, INT‟L CENTRE FOR TRADE & SUSTAINABLE DEV.
(2010), available at http://ictsd.org/downloads/2011/12/free-trade-of-pharmaceuticalproducts.pdf.
17
Ruse-Khan & Jaeger, supra note 16; Seuba, supra note 16. Ruse-Khan and Jaeger
have been the most vociferous in arguing that Article 10 of BMR authorizing seizure goods
in transit based on alleged IP infringement under of the domestic law of the transit country
may run counter to Article 52 of TRIPS which requires that border measures be applied
based on the “law of the country of importation.”
18
India WTO Complaint, supra note 3. India‟s comprehensive WTO complaint cited
violations of Paragraphs 2, 3, 4, and 7 of Article V and Article X of the GATT 1994
(unreasonable and discriminatory interference of legitimate trade using routes most
convenient for international transit); and Articles 2, 28, 31, 41 and 42 of the TRIPS
Agreement, especially in reference to the Doha Declaration and the August 6 Decision
(unreasonable interference with freedom of transit of generic medicines resulting in
unnecessary burdens and unwarranted delays and frustrating export of medicines lawfully
produced to countries where they could be lawfully consumed).
19
Marrakesh Agreement Establishing the World Trade Organization, art. 8(1), annex
1C, Apr. 15, 1994, 1867 U.N.T.S. 154, available at
http://www.wto.org/english/docs_e/legal_e/27-trips.pdf.
WWW.WCL.AMERICAN.EDU/PIJIP
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Agreement on Tariffs and Trade, the Doha Declaration on the TRIPS
Agreement and Public Health,20 and the Decision of 30 August 30 on
Paragraph 6 of the Doha Declaration.21 At a more fundamental level, legal
scholars criticized BMR 1383/2003 and the EU‟s multiple seizures of
generic medicines for violating core features of the international order
including: (a) the territoriality of IP rights, 22 (b) respect for the sovereign
“independence” of countries to adopt and implement TRIPS-compliant
patent regimes as they consider appropriate,23 (c) freedom of transit of
goods moving through a country‟s transportation systems in the stream of
international trade,24 and (d) the human right to health and of access to
essential medicines.25
These issues were placed squarely before the European Court of Justice
in two joined cases, C-446/09 and C-495/09 Philips/Nokia26 adjudicating
the legality of border actions by customs agents detaining IP-suspect goods,
temporarily warehoused or placed in external transit procedures, based on
mere suspicion of diversion and/or reliance on the manufacturing fiction.
On December 1, 2011, the European Court of Justice issued an opinion27
ruling that goods in customs suspensive procedures, including warehousing
and external transit, that are suspected of violating trademark, copyright,
20

Declaration on the TRIPS Agreement and Public Health, Ministerial Conference,
Fourth Session, Doha, Nov. 9-14 2001, WT/MIN(01)/DEC/1 (Nov 142001), available at
http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_e.htm.
21
Decision of the General Council of Aug. 30, 2003, Implementation of Paragraph 6
of the Doha Declaration on the TRIPS Agreement and Public Health, WT/L/540 (Sept. 1,
2003), available at http://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm.
22
Seuba, supra note 16, at 16-17; Ruse-Khan & Jaeger, supra note 16, at 518-519;
Abbott, supra note 12, at 44-45. The territoriality criticism is based on the premise that IPrelated acts done outside a nation‟s territory do not violate the territorial rights in force
within national borders and that medicines temporarily in-transit do not involve any
prohibited “use” of the patent (making, using, offering for sale, selling, or importing for
these purposes) within a country‟s territorial market.
23
Seuba, supra note 16, at 16-17; Ruse-Khan & Jaeger, supra note 16, at 521-524;
Abbott, supra note 12, at 44.
24
Seuba, supra note 16, at 9-10; Ruse-Khan & Jaeger, supra note 16, at 532-536;
Abbott, supra note 12, at 45-46.
25
Seuba, supra note 16, at 22-23; Ruse-Khan & Jaeger, supra note 16, at 529-532.
26
Case C-446/09, Koninklijke Philips Electronic (2010) OJ C 24/29, (relating to the
old, superseded Customs Regulation No. 3295/94); and Case C-446/09, Nokia Corporation
(2010) OJ C 37/22 (relating to BMR 1383/2003).
27
Joined Cases C‑446/09 & C‑495/09, Koninklijke Philips Electronics NV v.
Lucheng Meijing Indus. Co., Nokia Corp. v. Her Majesty‟s Comm‟rs of Revenue and
Customs, 2011 E.C.R. *** [hereinafter Philips/Nokia Judgment], available at
http://curia.europa.eu/juris/document/document.jsf?text=&docid=115783&pageIndex=0&d
oclang=en&mode=req&dir=&occ=first&part=1&cid=2701.
WWW.WCL.AMERICAN.EDU/PIJIP
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and design rights under EU Member State law: (1) could not even be
temporarily detained in the absence of evidence that the goods had been
sold, offered for sale or advertised in the EU or that there were other
indications that operators are about to direct the goods towards European
Union consumers or were otherwise disguising their commercial intentions;
and (2) could not be considered abandoned or destroyed unless a
substantive examination has proven that the challenged goods have been
sold, offered for sale or advertised to EU consumers or that there is
documentation showing that diversion is envisaged.28 Temporary detention
requires a showing, “based on the facts of the case”29 of a planned or
advertised sale or a lack of clarity about the intended destination of the
goods, the identity of the manufacturer or consignee, or a failure to

28

Id. at ¶79 contains the ruling of the Court:

Council Regulation (EC) No 3295/94 of 22 December 1994 laying down measures
concerning the entry into the Community and the export and re-export from the
Community of goods infringing certain intellectual property rights, as amended by
Council Regulation (EC) No 241/1999 of 25 January 1999, and Council Regulation
(EC) No 1383/2003 of 22 July 2003 concerning customs action against goods
suspected of infringing certain intellectual property rights and the measures to be taken
against goods found to have infringed such rights must be interpreted as meaning that:
–
goods coming from a non-member State which are imitations of goods protected
in the European Union by a trade mark right or copies of goods protected in the
European Union by copyright, a related right or a design cannot be classified as
„counterfeit goods‟ or „pirated goods‟ within the meaning of those regulations merely
on the basis of the fact that they are brought into the customs territory of the European
Union under a suspensive procedure;
–
those goods may, on the other hand, infringe the right in question and therefore
be classified as „counterfeit goods‟ or „pirated goods‟ where it is proven that they are
intended to be put on sale in the European Union, such proof being provided, inter alia,
where it turns that the goods have been sold to a customer in the European Union or
offered for sale or advertised to consumers in the European Union, or where it is
apparent from documents or correspondence concerning the goods that their diversion
to European Union consumers is envisaged;
–
in order that the authority competent to take a substantive decision may
profitably examine whether such proof and the other elements constituting an
infringement of the intellectual property right relied upon exist, the customs authority
to which an application for action is made must, as soon as there are indications before
it giving grounds for suspecting that such an infringement exists, suspend the release
of or detain those goods; and
–
those indications may include, inter alia, the fact that the destination of the
goods is not declared whereas the suspensive procedure requested requires such a
declaration, the lack of precise or reliable information as to the identity or address of
the manufacturer or consignor of the goods, a lack of cooperation with the customs
authorities or the discovery of documents or correspondence concerning the goods in
question suggesting that there is liable to be a diversion of those goods to European
Union consumers.
29
Id. at ¶ 62.
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cooperate with authorities.30 Final proof of a substantive EU IP violation
will in turn depend on firm, documented evidence of actual or planned
diversion.31 This judgment by the Court should constitute a death knell for
the “manufacturing” or “production” fiction that was used to justify seizure
and diversion of generic medicines in transit.32
CRITIQUE OF THE PROPOSED BORDER REGULATION – BETTER IS NOT
GOOD ENOUGH

III.

This is not the time to rehash the comprehensive critique of BMR
1383/2003, but rather to assess whether the Proposed Border Regulation
ameliorates its harsh and unwarranted application of customs detention to
in-transit generic medicines. Although the Proposed Border Regulation
improves due process to deter patent holders‟ abuse of border measures,33
recognizes the Doha Declaration,34 and requires prompt court action
30

Id. at ¶¶ 59, 60.

31

Id. at ¶¶ 68, 71.

32

See at ¶ 69.

33

See Proposed Border Regulation, supra note 6. New due process protections
include: right holder liability to declarants or the holder of the goods for wrongful
applications where the goods are determined not to be IP-infringing, but only if domestic
law so provides (Art. 26); reimbursement to the state for costs of destruction (Art. 27); time
limits on detentions pending decision on an application (Arts. 10 & 11); and goods holder
(alleged infringer) right to be heard (Arts. 16, 17 & 24). See generally Recital No. 15:
For further legal clarity and in order to protect the interests of legitimate
traders from possible abuse of the border enforcement provisions, it is appropriate
to modify the timelines for detaining goods suspected of infringing an intellectual
property right, the conditions in which information about consignments is to be
passed on to right-holders by customs authorities, the conditions for applying the
procedure allowing for destruction of the goods under customs control for
suspected infringements of intellectual property rights other than for counterfeit
and pirated goods and to introduce a provision allowing the holder of the goods to
express his/her views before the customs administration takes a decision which
would adversely affect him/her.
Collectively these procedural protections, though improvements, do not totally
ameliorate the risk of abusive applications for detention of goods nor remedy the harm
not only to declarants and holders of the goods but also to purchasers of essential lifesaving medicines and their ultimate consumers who may suffer adverse health effects
because of the interception of legitimate in-transit medicines.
34
Proposed Border Regulation, supra note 6 at Recital No. 17:
Under the "Declaration on the TRIPS Agreement and Public Health" adopted
by the Doha WTO Ministerial Conference on 14 November 2001, the TRIPS
Agreement can and should be interpreted and implemented in a manner supportive
of WTO Members' right to protect public health and, in particular, to promote
WWW.WCL.AMERICAN.EDU/PIJIP
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regarding detentions based on suspected patent violations,35 the proposal
still contains disruptive measures. These measures unjustifiably interfere
with the legitimate trade of generic medicines of assured quality, and cause
harm to vendors and shippers of the goods and to their purchasers and
consumers. It contains these negative features despite the efforts of leading
NGOs and commentators urging more extensive reforms that would have
eliminated the risks of patent-based and civil-trademark-based seizures of
generic medicines in transit.36
Problems with the Proposed Border Regulation include:
1. The proposed regulation continues coverage of patents,
supplementary protection certificates for medicinal products
(patent extensions), design rights, and civil trademark
infringements, and thus continues to threaten access to
medicines.37
In fact, the proposal extends border measures to entirely new
intellectual property rights, including trade names, topographies of
semiconductor products, utility models, and devices to circumvent
technological measures, as well as any exclusive intellectual
access to medicines for all. …”
It is important to note that this recital is preambular and imposes no direct
obligation on an EU Member State.
35
Id. at Recital 11; Art. 20.
Where goods suspected of infringing intellectual property rights are no
counterfeit or pirated goods, it may be difficult to determine upon mere visual
examination by customs authorities whether an intellectual property right might be
infringed. It is therefore appropriate to provide that proceedings should be
initiated, unless the parties concerned, namely the holder of the goods and the
right-holder, agree to abandon the goods for destruction. It should be for the
competent authorities dealing with such proceedings to determine whether an
intellectual property right has been infringed and to take appropriate decisions
concerning the infringements of intellectual property rights concerned.
36
See, e.g., Thomas Jaeger, Henning Grosse Ruse-Khan, Josef Drexl & Reto M. Hilty,
Statement of the Max Planck institute for Intellectual Property, Competition and Tax Law
on the Review of EU Legislation on Customs Enforcement of Intellectual Property Rights
(2010), available at http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1622619; Letter
from Public Citizen to European Commission (May 25, 2010), available at
http://www.citizen.org/documents/Public%20Citizen%20comments%20submitted%20to%
20DG%20TAXUD%20on%201383.pdf; Oxfam International, Public Consultation on the
Review of Council Regulation 1383/2003 (2010), available at
http://circa.europa.eu/Public/irc/taxud/consultation_ipr/library?l=/registered_organisations/
stichting_international/_EN_1.0_&a=d. Most civil society comments focused primarily on
the desirability of excluding patent rights from any revision of BMR 1383/2003.
37
Proposed Border Measure, supra note 6, Art. 2(1)(e) & (f).
WWW.WCL.AMERICAN.EDU/PIJIP
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property rights established by Union legislation in the future.38
Instead of continuing to cover patents, supplementary protection
certificates and expanding coverage to include utility models, civil
trademark rights, and design rights, the scope of the Proposed
Border Regulation should be restricted to criminal trademark
counterfeiting and copyright piracy as defined by Articles 61 and 51
footnotes 14(a) and (b) of the TRIPS Agreement.39 Coverage of
patents, supplementary protection certificates, utility models, design
rights, and civil trademark rights should be explicitly excluded. By
adopting such a limited, scope, the Proposed Border Regulation
would prevent seizures of generic medicines because of weak,
invalid or non-existent patent or utility model claims or because
confusing similarity in trade name, trademark, or trade dress.40
Moreover, it would leave ordinary commercial disputes involving
complex facts and IP rules to judicial resolution in the country of
38

Id. Recital 5; Art. 2(1)(j)-(m).
TRIPS, supra note 2019, Article 51 n. 14 reads:
For the purposes of this Agreement:
(a) “counterfeit trademark goods” shall mean any goods, including packaging,
bearing without authorization a trademark which is identical to the
trademark validly registered in respect of such goods, or which cannot be
distinguished in its essential aspects from such a trademark, and which
thereby infringes the rights of the owner of the trademark in question
under the law of the country of importation (emphasis added);
(b) “pirated copyright goods” shall mean any goods which are copies made
without the consent of the right holder or person duly authorized by the
right holder in the country of production and which are made directly or
indirectly from an article where the making of that copy would have
constituted an infringement of a copyright or a related right under the law
of the country of importation.
TRIPS Article 61, in relevant part reads:
Members shall provide for criminal procedures and penalties to be applied at
least in cases of willful trademark counterfeiting or copyright piracy on a
commercial scale. Remedies available shall include imprisonment and/or
monetary fines sufficient to provide a deterrent, consistently with the level of
penalties applied for crimes of a corresponding gravity. In appropriate cases,
remedies available shall also include the seizure, forfeiture and destruction of the
infringing goods and of any materials and implements the predominant use of
which has been in the commission of the offence. (Emphasis added.)
40
Some health officials are now arguing that it may be desirable to encourage generic
equivalents to have the same appearance or trade (size, shape, and color of the medicine) so
as to promote generic substitution and reduce prescription errors by pharmacists, to avoid
patient confusion, and to enhance patient adherence. Jeremy A. Greene & Aaron S.
Kesselheim, Why Do the Same Drugs Look Different? Pills, Trade Dress, and Public
Health, 365 NEW ENGL. J. MED. 83-89 (2011).
39
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importation pursuant to the governing laws of that country as
required by TRIPS.
2. The Proposed Border Regulation continues to authorize
application of the law of the transit country and the use of the
manufacturing fiction, both of which inappropriately permit the
seizure of generic medicines in transit.
Under the Proposed Border Regulation, the definition of "goods
suspected of infringing an intellectual property right” means “goods
with regard to which there is adequate evidence to satisfy customs
authorities that, in the Member State the goods are prima facie:
goods which are subject to an action infringing an intellectual
property right under the law of the Union or of that Member State
(emphasis added).”41 More precisely, the applicable law used to
determine whether “the use of … goods gives rise to suspicion of
infringement of an intellectual property right or has infringed an
intellectual property right” is that of “the law [of the] Member State
where the goods are found” (emphases added).42 This formulation is
slightly different than the formulation of Recital No. 8 of BMR
1383/2003 which stated that “[p]roceedings initiated to determine
whether an intellectual property right has been infringed under
national law will be conducted with reference to the criteria used to
establish whether goods produced in that Member State infringe
intellectual property rights (emphasis added).” The use of the
phrase “use of those goods” versus “goods produced” would not
seem to directly undermine the continuing viability of the
manufacturing fiction under national law. For example, Article 28
of the TRIPS Agreement covers both “manufacturing” (production)
and “use.”43 Moreover, the Proposed Border Regulation is clear that
41

Proposed Border Measure, supra note 6, Art. 2(7)(a). Although this language is
somewhat confusing, its main import is that the law of individual EU Member States will
continue to apply.
42
Id. Art. 3
Applicable Law: … the law of the Member State where the goods are found
in one of the situations referred to in Article 1(1) shall apply for the purpose of
determining whether the use of those goods gives rise to suspicion of infringement
of an intellectual property right or has infringed an intellectual property right
(emphasis added).
43
TRIPS, supra note 2119:
A patent shall confer on its owner the following exclusive rights: (a) where the
subject matter of a patent is a product, to prevent third parties not having the owner‟s
consent from the acts of: making, using, offering for sale, selling, or importing for
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it is not intended to affect in any way the laws of Member States.44
Accordingly, if a country maintains the manufacturing fiction with
respect to assessing the patent or supplementary protection status of
a medicine, as the Netherlands and other European countries clearly
do,45 then an in-transit generic medicine could still be seized,
adjudicated as an infringement, and thus destroyed, even if it was
lawfully produced in the country of manufacture and destined for
legal use in the final country of import. This fictive, non-territorial
application of domestic law to transit goods is in direct violation of
Articles 5246 and 51, footnote 1447 of the TRIPS Agreement, which
requires application of “the law of the importing country” when
assessing whether an intellectual property right at the border is
violated or whether a good is a trademark counterfeit. There is no
justification for applying fictive domestic IP law to goods that are
not “used” so as to violate IP rights within the territorial market of
the transit country. Applying such fictive rights, in essence becomes
an extra-territorial application of purely domestic IP law and IP
status to goods that are destined for commercialization or other use
within that territory. To apply such fictive territorial rules could
disrupt broad swathes of international trade using the most efficient
trade routes as permitted by GATT. Dangerously, there is no reason
that such fictive territoriality could not be extended with respect to
other territorial regimes including labor rights, environmental rights,
packaging/disclosure requirements, licensure, etc. Finally, any
continued use of the manufacturing fiction should now be decisively
illegal pursuant to the recent judgment of the European Court of
Justice.48

these purposes that product; (b) where the subject matter of a patent is a process, to
prevent third parties not having the owner‟s consent from the act of using the
process, and from the acts of: using, offering for sale, selling, or importing for these
purposes at least the product obtained directly by that process.
44
Proposed Border Measure, supra note 6, Art. 1.3.
45
Olivier Vrins, The Real Story of a Fiction: Transit after Montex under Regulation
(EC) 1383/2003, 5 J. INTELLECTUAL L. & PRAC. 358, 358-371 (2010).
46
TRIPS, supra note 19, Art. 52: “Any right holder initiating the procedures under
Article 51 shall be required to provide adequate evidence to satisfy the competent
authorities that, under the laws of the country of importation, there is prima facie an
infringement of the right holder‟s intellectual property right ….”
47
See supra note 37.
48
See supra notes 27-33.
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3. The exhortation for customs authorities to acknowledge
transshipment as occurring within the context of international
trade, and to "take account of any substantial likelihood of
diversion [of medicines] onto the market of the Union,"49 has no
teeth and has no meaningful definition of how the likelihood of
diversion is to be established.
Although Recital 17 says that customs authorities “should” take into
account any substantial likelihood of diversion, it does not require
them to do so. Likewise, although the actuality of imminent
diversion into the European market is the only legally permissible
basis upon which to base the territorial application of European IP
status for a particular product, there is no guidance on what level or
type of evidence of diversion would suffice. Mere suspicion of
diversion should clearly be insufficient, but should there instead be
evidence of planned purchase and distribution by an identified entity
within the domestic market? Would it be sufficient to show a past
practice of diversion by the manufacturer or distributor of the same
good in the recent past? All of these questions need to be directly
addressed and clarified at the very least by adopting explicitly the
framework adopted by the European Court of Justice.50 Even the
Court of Justice‟s ruling is undesirably weak with respect to
authorizing temporary detention pending final adjudication of
planned diversion directed at EU consumers. Accordingly, the
proposed “evidence of diversion” provision justifying even
temporary detention would be substantially strengthened if it were
incorporated into the actual text of the regulation itself and if it were
to say: “There may be no determination of prima facie suspicion of
or violation of a covered intellectual property right in the absence of
compelling evidence showing a substantial likelihood of imminent
diversion of the challenged goods by an identified party onto the
market of the European Union.”

49

Proposed Border Measure, supra note 6, Recital 17.
In particular with regard to medicines the passage of which across this
territory of the European Union, with or without transshipment, warehousing,
breaking bulk, or changes in the mode or means of transport, is only a portion of a
complete journey beginning and terminating beyond the territory of the Union,
customs authorities should, when assessing a risk of infringement of intellectual
property rights, take account of any substantial likelihood of diversion of these
goods onto the market of the Union.
50
See supra notes 27-33.
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4. The time period for declarants or the holder of goods to respond
to detention of suspect goods is too short.
Temporary suspension of the release of goods or their detention can
be pursued ex parte either by an application of the right-holder or
other identified surrogate using Articles 4-6 or by unilateral ex
officio action of customs authorities, who thereafter must request the
right holder to initiate an application, Article 17. In either event,
customs authorities are required to communicate their intentions to
the declarant or, in the case of detention, the holder of the goods
after the fact, and only then is the declarant or holder “given the
opportunity to express his/her views within three working days.”51
Upon granting an application, the competent customs department
must suspend the release of the goods or detain them and must
promptly notify both the holder of the decision (the right holder) and
the declarant or holder of the goods of its decision.52
Although
these notice and opportunity to be heard provisions are an
improvement over BMR 1383/2003, the three-day time period
granted to declarants and holders of the goods is insufficient to give
them fair opportunity to amass evidence concerning the lawful IP
status of the goods in issue and to confirm the ultimate destination
of in-transit goods outside the EU. Declarants and holders of goods
should be given at least 10 days for such a showing and there should
be additional provisions allowing for a further extension upon
proper motivation.
5. Even temporary detention of generic medicines adversely affects
the rights of intended purchasers and users and the Proposed
Border Regulation leaves them without a remedy.
A further requirement applying to non-counterfeit or pirated goods
(criminal trademark and copyright violations) – namely goods
alleged to have infringed design, patent, supplementary protection
certificates, utility model, or plant variety rights – is that they must
initiate proceedings for a court decision determining that the IP right
in question has been violated.53 However, the requirement of
additional court proceedings does not prevent pre-determination
seizure either upon application of the right-holder or even ex officio

51

Id. at Arts. 16.3 & 17.3. A longer time period of 20 days is granted when customs
officials propose to destroy goods in small consignments. Art. 24.4.
52
Id. at Arts. 16.4, 17.4.
53
Id. at Art. 20.1.
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by the customs authority. Admittedly, the goods will be detained,
pursuant to a granted application, for only a limited period of time –
10 days – unless proceedings are promptly initiated, but goods
thereafter can ordinarily be detained until the court proceedings have
ended, a time period that can last months or even years. 54 There are
procedures for release of goods upon payment of adequate security,
and there are eventual remedies for applications and proceedings
where it is determined that IP rights have not been violated, but
these partial remedies do not always compensate holders of the
goods for lost commercial opportunities and disruptions of their
business, nor do they provide remedies for intended purchasers and
ultimate consumers whose needs for life-saving and healthenhancing medicines have been frustrated. Buyers, including
government purchasers might have to use special and higher cost
procurement methods to get emergency supplies. If they are fiscally
unable to do so, or if suppliers cannot meet their needs immediately
because of orders from other customers, public health programs and
the immediate medical needs of patients might not be met. At
present, there are no remedies for such purchasers or consumers, nor
even are there confirmed remedies for declarants or holders of goods
unless, and only to the extent that, the law of the country in question
so provides.55 The Proposed Border Regulation should be amended
to provide much more certain and robust remedies for declarants and
holders of goods and for purchasers and customers who may have
suffered harm as a proximate result of right-holders‟ unsuccessful
actions under the regulation.

54

This ten-day period can be extended another ten days upon application except in the
case of perishable goods. Id. at Art. 20.4. There are provisions for the declarant or holder
of the goods to seek their release from detention, but only if adequate security has been
posted, no precautionary measures (preliminary injunctions) have been entered, and all
customs formalities completed; Art. 21.1.
55
Id. at Art. 26:
Where a procedure duly initiated pursuant to this Regulation is
discontinued owing to an act or omission on the part of the holder of the
decision granting the application or where the goods in question are
subsequently found not to infringe an intellectual property right, the holder of
the decision granting the application shall be liable towards the persons
involved in a situation referred to in Article 1(1) in accordance with the
legislation of the Member State where the goods were found.
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IV.

CONCLUSION

A better regulation would have excluded coverage of patents,
supplementary protection certificates, utility models, design rights, and civil
trademark violations and/or specifically prevented application of a domestic
manufacturing or use fiction with respect to in-transit goods. It would have
much more directly addressed the Doha Declaration and clarified that no
customs action should be undertaken with respect to in-transit generic
medicines lawfully produced in the country of origin and lawfully imported
into the country of use, unless there is concrete and compelling evidence of
imminent diversion of the goods into the European market by an identified
party. Declarants and holders of goods should be given more meaningful
opportunities to object to detention and seizure of their goods and to oppose
applications by right holders. And, the provisions for remedies when right
holders‟ applications are unsuccessful should be expanded both for
declarants/holders-of-goods and ultimate purchasers/consumers whose
interests have been proximately harmed by the wrongful detention and/or
destruction of goods.
Instead, the EC has attempted to strengthen the enforcement rights of IP
right holders and has once again passed the buck to country-specific IP
legislative standards and enforcement criteria. These country specific
standards and criteria, including the manufacturing/domestic-use fiction,
may once again run afoul of fundamental precepts of intellectual property
law, the TRIPS Agreement and GATT, and public health needs enshrined in
the Doha Declaration and in other binding human rights instruments.
Europe has treated its reform obligations primarily as an exercise in
balancing expanded intellectual property protections against greater due
process rights, without addressing the most fundamental defects in the BMR
1383/2003 regime, a defect that has also been identified by the European
Court of Justice. Accordingly, European parliamentarians should reject the
Proposed Border Regulation in its current form as should India and Brazil
with respect to their suspended WTO complaints.
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